Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.

Ueno S, Tatetsu H, Hata H, Iino T, Niiro H, Akashi K, Tenen DG, Mitsuya H, Okuno Y.

Oncogene. 2009 Nov 19;28(46):4116-25. doi: 10.1038/onc.2009.263. Epub 2009 Sep 14.

2.

Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H, Tenen DG, Okuno Y.

Cancer Res. 2007 Jun 1;67(11):5328-36.

3.

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.

Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.

Blood. 2013 Feb 7;121(6):962-70. doi: 10.1182/blood-2012-05-431429. Epub 2012 Dec 4.

5.

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.

Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F.

Cancer Biol Ther. 2010 Dec 1;10(11):1201-14. Epub 2010 Dec 1.

6.

Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.

Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, Delgado M, Aires A, Ocio EM, García-Sanz R, San Miguel JF, Gutiérrez NC.

Haematologica. 2013 Apr;98(4):640-8. doi: 10.3324/haematol.2012.070011. Epub 2012 Oct 25.

7.

Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.

Hong S, Kim HY, Kim J, Ha HT, Kim YM, Bae E, Kim TH, Lee KC, Kim SJ.

J Biol Chem. 2013 Feb 1;288(5):3560-70. doi: 10.1074/jbc.M112.400408. Epub 2012 Dec 19.

8.

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.

Oncogene. 2002 Aug 22;21(37):5673-83.

9.
10.

Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

Berg D, Stühmer T, Siegmund D, Müller N, Giner T, Dittrich-Breiholz O, Kracht M, Bargou R, Wajant H.

FEBS J. 2009 Dec;276(23):6912-27. doi: 10.1111/j.1742-4658.2009.07388.x. Epub 2009 Nov 6.

11.

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.

Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.

Leukemia. 2004 Nov;18(11):1780-8.

PMID:
15385934
12.

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.

Maginn EN, Browne PV, Hayden P, Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM.

Br J Cancer. 2011 Jan 18;104(2):281-9. doi: 10.1038/sj.bjc.6606035. Epub 2010 Dec 21.

13.

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.

Blood. 2012 Aug 2;120(5):1095-106. doi: 10.1182/blood-2012-03-415984. Epub 2012 Jun 20.

14.

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S.

Clin Cancer Res. 2007 Oct 15;13(20):6010-8.

15.

PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity.

Tschan MP, Reddy VA, Ress A, Arvidsson G, Fey MF, Torbett BE.

Oncogene. 2008 May 29;27(24):3489-93. doi: 10.1038/sj.onc.1211004. Epub 2008 Jan 14.

PMID:
18193090
17.

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.

Barbetti V, Tusa I, Cipolleschi MG, Rovida E, Dello Sbarba P.

Cell Death Dis. 2013 Mar 14;4:e536. doi: 10.1038/cddis.2013.49.

18.

Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3.

Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T, Ikeda Y.

Blood. 2000 Sep 15;96(6):2005-11.

19.

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.

Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, Fadeel B, Zheng C.

Mol Immunol. 2010 Aug;47(14):2388-96. doi: 10.1016/j.molimm.2010.05.003. Epub 2010 Jun 9.

PMID:
20542572
20.

Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis.

Park WH, Kim ES, Kim BK, Lee YY.

Int J Oncol. 2003 Jul;23(1):197-204.

PMID:
12792794
Items per page

Supplemental Content

Write to the Help Desk